Investor Presentaiton
INO-3106 Pilot Study in RRP - Completed
TRIAL: INO-3106 (for HPV 6-caused RRP)
Phase 1 pilot,
single-site,
clinical study
x2
Enrolled 2 adult
patients with RRP,
HPV 6+
4 doses of vaccine,
3 weeks apart on
Day 0, Weeks 3, 6, 9
4
CELLECTRA-delivered
INO-3106 (only for HPV 6)
plasmid encoded antigens
Two RRP patients
had prior surgeries
every 6 months
After receiving 4 doses, 1 patient
has gone >915 days without
surgery, and the second went
584 days without surgery
Open-label Phase 1/2 study to
evaluate efficacy, safety,
tolerability, and immunogenicity
of INO-3107 (for HPV 6 and
11)
25
25
Published in Vaccines (MDPI); entitled "Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or
Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis"; January 23, 2020.
INOVIO
POWERING DNA MEDICINESView entire presentation